Although to our knowledge, the model-proposed treatment framework of combining MET TKIs with downstream kinase inhibitors (e.g., MEK, ERK, AKT inhibitors) has not yet entered clinical testing for MET-aberrant lung cancer patients, similar routines (of combining mutation-targeted TKIs with kinase inhibitors) have proven successful in other point mutation-driven NSCLC (e.g., BRAF) (Planchard et al., 2024). Here, AKT1 is linked to lung cancer.